Renin-angiotensin-aldosterone system (RAAS) dependent hypertension, diabetes featured by hyperglycemia, hyperlipidemia, hyperuricemia, hyperhomocysteinemia, overweight or obesity etc., represent the major types of endocrine and metabolic disorders which contribute most to the development of atherosclerosis-based cardiovascular diseases. In clinical studies, these diseases comprise nonfatal myocardial infarction, nonfatal cerebral infarction, or even cardiovascular death, termed 3 major adverse cardiovascular events (3p MACE). On one side, these endocrine or metabolic dysfunctions are the upstream risk factors of cardiovascular diseases. Meanwhile, more and more antidiabetic drugs, e.g., glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose transporter-2 inhibitors (SGLT2i) etc., are reported to have not only blood glucose lowering effects, but also have direct cardiovascular protective effects independent of the glucose lowering effects. Regarding the close relationship between endocrine or metabolic disorders and downstream cardiovascular outcomes, a call for a new subspeciality in internal medicine, cardiometabolic medicine, was proposed in Am J Med, 2019. Recently, many basic or clinical studies focused on endocrine and metabolic cardiovascular outcomes. The goal of this Research Topic is to compile recent advances concentrating in this area, both in terms of basic and clinical aspects, to further value the cardiovascular outcomes in treating endocrine and metabolic diseases.

Of evidence-based recommendations -- Introduction -- Overweight and obesity: background -- Examination of randomized controlled trial evidence -- Treatment guidelines -- Summary of recommendations -- Future research.

Established as the foremost text in the field, Principles and Practice of Endocrinology and Metabolism is now in its thoroughly revised, updated Third Edition. This practical, clinically relevant, and comprehensive text covers the entire field of endocrinology and metabolism, including the diffuse endocrine system; morphology and physiology; diagnosis and treatment of endocrine diseases; endocrinology of the female; hormones and cancer; and much more. The Third Edition contains new chapters reflecting the latest advances and features expanded coverage of genetics and the endocrinology of sepsis. More than 1,400 illustrations complement the text. A drug formulary appears at the back of the book.

Advances in Adrenocortical Hyperfunction Research and Treatment / 2012 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Adrenocortical Hyperfunction in a concise format. The editors have built Advances in Adrenocortical Hyperfunction Research and Treatment / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Adrenocortical Hyperfunction in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Advances in Adrenocortical Hyperfunction Research and Treatment / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Establishing an integrative approach to the understanding and management of PCOS Polycystic ovary syndrome (PCOS) is the most frequent disorder affecting women of reproductive age. Recent years have shown substantial advances in our understanding of the complex genetic, biochemical, metabolic, cardiovascular, and reproductive issues associated with PCOS. This book presents a comprehensive overview of recent clinical developments in identifying the phenotypic expression of women with PCOS resulting in a completely new recognition of its phenotypic variability. Metabolic and cardiovascular consequences of the syndrome are discussed in detail. Advances made in dealing with secondary forms of PCOS-like syndromes are presented as well as specific therapies of clinical manifestations and their outcomes. Additionally, a number of hot topics are included presenting genetic developments, endothelial causes leading to unfavorable outcomes, and novelties in therapeutic approaches dealing with metabolic and reproductive consequences. Covering phenotypic characteristics, diagnostic criteria, central pathophysiological mechanisms, metabolic, cardiovascular and reproductive aspects, and modern therapeutic approaches, this book is a useful tool for general practitioners, gynecologists, pediatricians, internists, endocrinologists, as well as cardiologists.

Diabetes and hypertension have evolved as two of the modern day epidemics affecting millions of people around the world. These two common co-morbidities lead to substantial increase in cardiovascular disease, the major cause of morbidity and mortality of adults around the world. In Diabetes and Hypertension: Evaluation and Management, a panel of renowned experts address a range of critical topics -- from basic concepts in evaluation and management of diabetes and hypertension, such as dietary interventions, to evaluation and management of secondary hypertension in clinical practice. Other chapters focus on high cardiovascular risk populations such as those with coronary heart disease, chronic kidney disease and minority patients. In addition, evolving concepts and new developments in the field are presented in other chapters, such as prevention of type 2 diabetes and the epidemic of sleep apnea and its implication for diabetes and hypertension evaluation and management. An important title covering two of the most troubling disorders of our time, Diabetes and Hypertension: Evaluation and Management will provide the busy practitioner with cutting edge knowledge in the field as well as practical information that can translate into better care provided to the high-risk population of diabetics and hypertensive patients.